Microbiome-Based Interventions in Cancer Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 23514
Special Issue Editor
2. London Regional Cancer Program, Lawson Health Research Institute, London, ON N6A 5W9, Canada
Interests: immunotherapy; microbiome; melanoma; RCC; T cells; immune-related adverse events; fecal microbiota transplant
Special Issue Information
Dear Colleagues,
Recent landmark discoveries revealed the role of the gut microbiome as a tumor-extrinsic factor in modulating antitumor immunity and affecting clinical response to immune checkpoint blockade (ICB) in cancer patients. These findings featured the gut microbiome as a potential biomarker for response to ICB treatment. Moreover, responder-derived fecal microbiota transplantation (FMT) sensitized antiprogrammed death 1 (PD1)-refractory melanoma tumors to immunotherapy. The challenge facing researchers in this fast-growing area is pinpointing the underlying mechanisms of action of the microorganisms living along barrier tissues and how they interact with the host and tumor cells that can affect a cancer patient’s response to drugs that modulate the immune system. Moreover, it is now crucial to understand how different microbial signatures can be used as biomarkers of response and toxicity in the area of immunotherapy.
We are pleased to invite you to submit research, commandry, or review articles from your work that describe the role of the gut or tumor microbiome in modulating antitumor immunity and response to immunotherapy. Your article can be in the area of therapeutics, diagnostics, biomarker, or mechanistic studies about the effect of microbiome and microorganisms on antitumor immunity.
This Special Issue aims to gather novel data or perspectives in the area of oncomicrobiome and how microbiome-based strategies can be used to 1) select potential responders to immunotherapy, 2) modulate patients’ response to these drugs, and 3) prevent toxicity in patients receiving immunotherapy.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Role of microbiome in systemic and local cancer treatments;
- The effect of the gut and tumor microbiome on response to immunotherapy with checkpoint inhibitors or adoptive cell therapy;
- The role of microbiome on inducing or preventing immune-related toxicities from immunotherapy;
- Mechanisms of immune modulation by gut microbiome or their products;
- Microbiome-based biomarker strategies for patients receiving cancer immunotherapy;
- Microbiome-based combination therapies in the area of cancer immunotherapy.
I look forward to receiving your contributions.
Dr. Saman Maleki Vareki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microbiome
- microbiota
- cancer
- immunotherapy
- immune checkpoint blockade
- toxicity
- immune-related adverse events
- biomarker
- metabolites
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.